HRP20230929T1 - Stabilni pripravci semaglutida i njihova upotreba - Google Patents
Stabilni pripravci semaglutida i njihova upotreba Download PDFInfo
- Publication number
- HRP20230929T1 HRP20230929T1 HRP20230929TT HRP20230929T HRP20230929T1 HR P20230929 T1 HRP20230929 T1 HR P20230929T1 HR P20230929T T HRP20230929T T HR P20230929TT HR P20230929 T HRP20230929 T HR P20230929T HR P20230929 T1 HRP20230929 T1 HR P20230929T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- preparation according
- kit
- preceding patent
- concentration
- Prior art date
Links
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 title claims 4
- 229950011186 semaglutide Drugs 0.000 title claims 4
- 108010060325 semaglutide Proteins 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Tekući farmaceutski pripravak, naznačen time što sadrži semaglutid, sredstvo za izotoničnost i histidin, što je koncentracija histidina 0,5-100 mM, te što je pH pripravka u rasponu od 6,0-10,0.
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je koncentracija histidina 0,5-15 mM.
3. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je pripravak vodena otopina, koja sadrži najmanje 60% (tež./tež.) vode, primjerice najmanje 70% (tež./tež.) vode ili najmanje 80% (tež./tež.) vode.
4. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je koncentracija semaglutida 0,1-15 mg/ml pripravka.
5. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je koncentracija semaglutida 0,1-10 mg/ml pripravka.
6. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što pripravak dodatno sadrži jedno ili više farmaceutski prihvatljivih pomoćnih sredstava, poput pufera.
7. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što pripravak sadrži fosfatni pufer.
8. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što pripravak sadrži dinatrijev hidrogenfosfat dihidrat kao pufer.
9. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je sredstvo za izotoničnost propilen-glikol.
10. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je pripravak u napunjenoj štrcaljki ili ulošku.
11. Komplet, naznačen time što sadrži farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva i upute o upotrebi.
12. Komplet u skladu s patentnim zahtjevom 11, naznačen time što komplet sadrži napunjenu štrcaljku namijenjenu primjeni farmaceutskog pripravka na subjektu.
13. Komplet u skladu s patentnim zahtjevom 11, naznačen time što komplet sadrži trajnu brizgalicu ili napunjenu brizgalicu namijenjenu primjeni farmaceutskog pripravka na subjektu.
14. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačen time što je namijenjen upotrebi kao medikament.
15. Farmaceutski pripravak u skladu s patentnim zahtjevom 14, naznačen time što je namijenjen upotrebi u liječenju dijabetesa ili pretilosti.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18202801 | 2018-10-26 | ||
EP19158226 | 2019-02-20 | ||
PCT/EP2019/079214 WO2020084126A1 (en) | 2018-10-26 | 2019-10-25 | Stable semaglutide compositions and uses thereof |
EP19801228.8A EP3870213B1 (en) | 2018-10-26 | 2019-10-25 | Stable semaglutide compositions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230929T1 true HRP20230929T1 (hr) | 2023-11-24 |
Family
ID=68503076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230929TT HRP20230929T1 (hr) | 2018-10-26 | 2019-10-25 | Stabilni pripravci semaglutida i njihova upotreba |
Country Status (21)
Country | Link |
---|---|
US (1) | US20210379159A1 (hr) |
EP (1) | EP3870213B1 (hr) |
JP (1) | JP7422754B2 (hr) |
KR (1) | KR20210087465A (hr) |
CN (1) | CN112912100A (hr) |
AU (1) | AU2019363725B2 (hr) |
BR (1) | BR112021006598A2 (hr) |
CA (1) | CA3116271A1 (hr) |
CL (1) | CL2021000938A1 (hr) |
CO (1) | CO2021005915A2 (hr) |
ES (1) | ES2954584T3 (hr) |
HR (1) | HRP20230929T1 (hr) |
HU (1) | HUE062893T2 (hr) |
IL (1) | IL281938B2 (hr) |
MX (1) | MX2021004331A (hr) |
PE (1) | PE20211492A1 (hr) |
PH (1) | PH12021550705A1 (hr) |
PL (1) | PL3870213T3 (hr) |
RS (1) | RS64438B1 (hr) |
SG (1) | SG11202103137WA (hr) |
WO (1) | WO2020084126A1 (hr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3870213T3 (pl) | 2018-10-26 | 2023-11-20 | Novo Nordisk A/S | Stabilne kompozycje semaglutydu i ich zastosowania |
WO2021105393A1 (en) * | 2019-11-29 | 2021-06-03 | Novo Nordisk A/S | Processes for obtaining stable glp-1 compositions |
IL294521A (en) | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
CA3237796A1 (en) * | 2021-11-12 | 2023-05-19 | Zhenbin Li | Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof |
CN114660214B (zh) * | 2022-02-18 | 2024-04-05 | 兰州积石药业有限公司 | 一种司美格鲁肽的液相色谱检测方法及其应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10399015I1 (de) | 1991-12-20 | 2012-05-03 | Novo Nordisk As | Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält |
DK136492D0 (da) * | 1992-11-10 | 1992-11-10 | Novo Nordisk As | A pharmaceutical formulation |
CA2309818C (en) | 1997-11-12 | 2009-05-05 | Alza Corporation | Buffered drug formulations for transdermal electrotransport delivery |
GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
ES2298378T3 (es) * | 2001-06-28 | 2008-05-16 | Novo Nordisk A/S | Formulacion estable de glp-1 modificado. |
US20060287221A1 (en) * | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
HUE043210T2 (hu) * | 2003-11-20 | 2019-08-28 | Novo Nordisk As | Injekciós eszközök elõállítására optimális propilénglikol-tartalmú peptidkészítmények |
US20080280814A1 (en) * | 2004-09-17 | 2008-11-13 | Novo Nordisk A/S | Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide |
TWI372629B (en) * | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
EP2036539A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
WO2011109787A1 (en) * | 2010-03-05 | 2011-09-09 | Conjuchem, Llc | Methods of administering insulinotropic peptides |
SI3326620T1 (sl) | 2010-12-16 | 2020-07-31 | Novo Nordisk A/S | Trdne sestave, ki vsebujejo agonist GLP-1 in sol N-(8-(2-hidroksibenzoil)amino)kaprilne kisline |
US20120208755A1 (en) * | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
EP2820038B1 (en) * | 2012-03-01 | 2020-06-17 | Novo Nordisk A/S | Glp-1 prodrugs |
EP4324475A1 (en) | 2012-03-22 | 2024-02-21 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
CN103566354B (zh) * | 2012-07-25 | 2017-12-05 | 江苏豪森药业集团有限公司 | 含有glp‑1类似物的衍生物或其可药用盐的药物组合物 |
CN104717972A (zh) * | 2012-10-17 | 2015-06-17 | 诺和诺德A/S(股份有限公司) | 用于口服肽递送的脂肪酸酰化氨基酸 |
US9956287B2 (en) * | 2013-02-06 | 2018-05-01 | Perosphere Inc. | Stable glucagon formulations |
JP2014214153A (ja) | 2013-04-30 | 2014-11-17 | ニプロ株式会社 | 水溶液製剤およびその製造方法 |
MX2015016564A (es) * | 2013-06-20 | 2016-04-15 | Novo Nordisk As | Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos. |
WO2016038521A1 (en) * | 2014-09-08 | 2016-03-17 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of liraglutide |
WO2016077220A1 (en) * | 2014-11-10 | 2016-05-19 | Mb2 Llc | Gip/glp-1 co-agonist peptides for human administration |
WO2016083499A1 (en) * | 2014-11-27 | 2016-06-02 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
KR20180135012A (ko) * | 2016-04-28 | 2018-12-19 | 노보 노르디스크 에이/에스 | 심혈관 병태에서의 세마글루타이드 |
CN107661288A (zh) * | 2016-07-29 | 2018-02-06 | 江苏泰康生物医药有限公司 | 含有glp‑1 类似物融合蛋白的稳定液体制剂及其制备 |
CN107952064B (zh) * | 2016-10-14 | 2023-10-20 | 江苏豪森药业集团有限公司 | 含有聚乙二醇洛塞那肽的药物制剂及其制备方法 |
CN108210890A (zh) * | 2016-12-09 | 2018-06-29 | 江苏泰康生物医药有限公司 | 重组人胰高血糖素样肽-1类似物融合蛋白的新型稳定制剂 |
GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
PL3870213T3 (pl) | 2018-10-26 | 2023-11-20 | Novo Nordisk A/S | Stabilne kompozycje semaglutydu i ich zastosowania |
-
2019
- 2019-10-25 PL PL19801228.8T patent/PL3870213T3/pl unknown
- 2019-10-25 KR KR1020217014336A patent/KR20210087465A/ko not_active Application Discontinuation
- 2019-10-25 CN CN201980070660.8A patent/CN112912100A/zh active Pending
- 2019-10-25 CA CA3116271A patent/CA3116271A1/en active Pending
- 2019-10-25 SG SG11202103137WA patent/SG11202103137WA/en unknown
- 2019-10-25 JP JP2021521260A patent/JP7422754B2/ja active Active
- 2019-10-25 AU AU2019363725A patent/AU2019363725B2/en active Active
- 2019-10-25 HR HRP20230929TT patent/HRP20230929T1/hr unknown
- 2019-10-25 RS RS20230658A patent/RS64438B1/sr unknown
- 2019-10-25 BR BR112021006598A patent/BR112021006598A2/pt unknown
- 2019-10-25 PE PE2021000506A patent/PE20211492A1/es unknown
- 2019-10-25 MX MX2021004331A patent/MX2021004331A/es unknown
- 2019-10-25 ES ES19801228T patent/ES2954584T3/es active Active
- 2019-10-25 WO PCT/EP2019/079214 patent/WO2020084126A1/en active Application Filing
- 2019-10-25 US US17/288,128 patent/US20210379159A1/en active Pending
- 2019-10-25 IL IL281938A patent/IL281938B2/en unknown
- 2019-10-25 EP EP19801228.8A patent/EP3870213B1/en active Active
- 2019-10-25 HU HUE19801228A patent/HUE062893T2/hu unknown
-
2021
- 2021-03-29 PH PH12021550705A patent/PH12021550705A1/en unknown
- 2021-04-15 CL CL2021000938A patent/CL2021000938A1/es unknown
- 2021-05-05 CO CONC2021/0005915A patent/CO2021005915A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20211492A1 (es) | 2021-08-11 |
PH12021550705A1 (en) | 2021-11-03 |
EP3870213B1 (en) | 2023-06-07 |
MX2021004331A (es) | 2021-05-27 |
SG11202103137WA (en) | 2021-04-29 |
IL281938B2 (en) | 2024-04-01 |
CN112912100A (zh) | 2021-06-04 |
US20210379159A1 (en) | 2021-12-09 |
EP3870213A1 (en) | 2021-09-01 |
JP2022505290A (ja) | 2022-01-14 |
AU2019363725A1 (en) | 2021-05-20 |
AU2019363725B2 (en) | 2024-05-02 |
CA3116271A1 (en) | 2020-04-30 |
KR20210087465A (ko) | 2021-07-12 |
IL281938A (en) | 2021-05-31 |
PL3870213T3 (pl) | 2023-11-20 |
ES2954584T3 (es) | 2023-11-23 |
CO2021005915A2 (es) | 2021-08-09 |
IL281938B1 (en) | 2023-12-01 |
WO2020084126A1 (en) | 2020-04-30 |
HUE062893T2 (hu) | 2023-12-28 |
RS64438B1 (sr) | 2023-09-29 |
BR112021006598A2 (pt) | 2021-07-06 |
JP7422754B2 (ja) | 2024-01-26 |
CL2021000938A1 (es) | 2021-09-10 |
EP3870213C0 (en) | 2023-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
JP2018138578A5 (hr) | ||
ES2911207T3 (es) | Composiciones de insulina de acción rápida | |
AR110986A2 (es) | Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso | |
AR111572A2 (es) | Formas farmacéuticas que contienen vardenafilo | |
AR112480A1 (es) | Composiciones de glp-1 y sus usos | |
AR052198A1 (es) | Formulaciones anticuerpo anti a beta | |
BR0213143A (pt) | Composições lìquidas para administração oral contendo guaifenesina e um copolìmero de bloco polioxialquileno | |
GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
HRP20121072T1 (hr) | Postupci za davanje tetrahidrobiopterina, povezani pripravci i postupci mjerenja | |
AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
HRP20110801T1 (hr) | Tekući oblik fsh | |
PA8542701A1 (es) | Composición parenteral reconstituible | |
HRP20120235T1 (hr) | Formulacija tekućeg hormona rasta | |
ES2720954T3 (es) | Formulaciones estabilizadas de estatina | |
BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
JP2015535237A5 (hr) | ||
RU2015119603A (ru) | Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc | |
PE20230819A1 (es) | Composiciones y usos de glp-1 | |
KR20140025314A (ko) | 복합 조성물 | |
JP2020500864A5 (hr) | ||
EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
US9561204B2 (en) | Effervescent compositions containing N-acetylcysteine | |
EA023535B9 (ru) | Композиция водного радиопротекторного фармацевтического раствора и способ предотвращения, снижения или исключения эффектов ионизирующей радиации | |
HRP20211492T1 (hr) | Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja |